Promising long-term disease control and survival with pembrolizumab and cabozantinib for head and neck cancer. Nierengarten MB. Cancer 2024;130:3947.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Promising long-term disease control and survival with pembrolizumab and cabozantinib for head and neck cancer. Cancer 2024;130:3947.
PMID: 39520311